

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/207083>

Please be advised that this information was generated on 2019-12-31 and may be subject to change.



Short Communication

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study



Onno Akkerman^{a,b}, Alena Aleksa^c, Jan-Willem Alffenaar^{d,e,f}, Nada Hassan Al-Marzouqi^g, Miguel Arias-Guillén^h, Evgeny Belilovskiⁱ, Enrique Bernal^j, Martin J. Boeree^k, Sergey E. Borisovⁱ, Judith Bruchfeld^l, Julen Cadiñanos Loidi^m, Qingshan Caiⁿ, Jose A. Caminero^{o,p}, Jose Joaquín Cebrian Gallardo^q, Rosella Centis^r, Luigi Ruffo Codecasa^s, Lia D'Ambrosio^t, Margareth Dalcolmo^u, Edvardas Danila^v, Masoud Dara^w, Edita Davidavičienė^x, Lina Davies Forsman^l, Jorge De Los Rios Jefe^y, Justin Denholm^z, Raquel Duarte^a, Seifeldin Eltaeb Elamin^b, Maurizio Ferrarese^s, Alexey Filippovⁱ, Shashank Ganatra^c, Ana Garcia^d, José-María García-García^e, Regina Gayoso^u, Angela Maria Giraldo Montoya^f, Roscio Gomez Gomez Rosso^g, Gina Gualano^h, Wouter Hoefsloot^k, Biljana Ilievaska-Poposka^l, Jerker Jonsson^j, Elena Khimova^k, Liga Kuksa^l, Heinke Kunst^m, Rafael Laniado-Laborínⁿ, Yang Li^o, Cecile Magis-Escurra^k, Vinicio Manfrin^p, Selene Manga^q, Valentina Marchese^r, Elena Martínez Robles^s, Andrei Maryandyshev^k, Alberto Matteelli^r, Giovanni Battista Migliori^{r,*}, Jai B. Mullerpattan^c, Marcela Munoz-Torrico^t, Hamdan Mustafa Hamdan^b, Magnolia Nieto Marcos^u, Noorliza Mohamad Noordin^v, Domingo Juan Palmero^d, Fabrizio Palmieri^h, Marie-Christine Payen^w, Alberto Piubello^{x,y}, Emanuele Pontali^z, Agostina Pontarelli^{aA}, Sarai Quirós^{aB}, Adrian Rendon^{aC}, Alena Skrahina^{aD}, Agnese Šmite^L, Ivan Solovic^{aE}, Giovanni Sotgiu^{aF}, Mahamadou Bassirou Souleymane^y, Antonio Spanevello^{aG,aH}, Maja Stošić^{aI}, Marina Tadolini^{aJ}, Simon Tiberi^{aK}, Zarir Farokh Udwardia^C, Martin van den Boom^w, Marisa Vescovo^D, Pietro Viggiani^{aA}, Dina Visca^{aG,aH}, Dmitry Zhurkin^{aD}, Matteo Zignol^{aL}, The members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring

* Corresponding author at: Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Via Roncaccio 16, Tradate, Varese, 21049, Italy.

E-mail addresses: o.w.akkerman@umcg.nl (O. Akkerman), alex_helen2001@mail.ru (A. Aleksa), j.w.c.alfenaar@umcg.nl (J.-W. Alffenaar), nada.almarzouqi@moh.gov.ae (N.H. Al-Marzouqi), miguelariasguillen@gmail.com (M. Arias-Guillén), belilovsky@gmail.com (E. Belilovski), ebm.hgurs@gmail.com (E. Bernal), Martin.Boeree@radboudumc.nl (M.J. Boeree), sebarsik@gmail.com (S.E. Borisov), judith.bruchfeld@ki.se (J. Bruchfeld), julen.cadinanos@hgivilalba.es (J. Cadiñanos Loidi), caiqs66@163.com (Q. Cai), jcamlun@gobiernodecanarias.org (J.A. Caminero), jcebrian@hcs.es (J.J. Cebrian Gallardo), rosella.centis@icsmaugeri.it (R. Centis), luigiruffo.codecasa@ospedaleniguarda.it (L.R. Codecasa), liadambrosio59@gmail.com (L. D'Ambrosio), margarethdalcolmo@gmail.com (M. Dalcolmo), Edvardas.Danila@santa.lt (E. Danila), daram@who.int (M. Dara), Edita.Davidaviciene@santa.lt (E. Davidavičienė), lina.davies.forsman@ki.se (L. Davies Forsman), jodelosrios@yahoo.com (J. De Los Rios Jefe), justin.denholm@mh.org.au (J. Denholm), raquelafduarte@gmail.com (R. Duarte), seifeldin61@gmail.com (S.E. Elamin), Maurizio.Ferrarese@ospedaleniguarda.it (M. Ferrarese), alex.phil.2010@yandex.ru (A. Filippov), shashankganatra11@gmail.com (S. Ganatra), angarcia111@hotmail.com (A. Garcia), josemariagarcia@gmail.com (J.-M. García-García), regina.gayoso@gmail.com (R. Gayoso), angelagiral@gmail.com (A.M. Giraldo Montoya), ros-cio@hotmail.com (R.G. Gomez Rosso), gina.gualano@inmi.it (G. Gualano), Wouter.Hoefsloot@radboudumc.nl (W. Hoefsloot), biljana.ilievaska@yahoo.com (B. Ilievaska-Poposka), jerker.jonsson@folkhalsomyndigheten.se (J. Jonsson), lenka.ro4eva.2013@yandex.ru (E. Khimova), Liga.Kuksa@aslimnica.lv (L. Kuksa), h.kunst@qmul.ac.uk (H. Kunst), rafaellaniado@gmail.com (R. Laniado-Laborín), losty34217@gmail.com (Y. Li), Cecile.Magis-Escurra@radboudumc.nl (C. Magis-Escurra), vinicio.manfrin@aulss8.veneto.it (V. Manfrin), seleneperu@yahoo.com.mx (S. Manga), v.marchese@unibs.it (V. Marchese), maryandyshev@mail.ru (A. Maryandyshev), alberto.matteelli@unibs.it (A. Matteelli), giovannibattista.migliori@icsmaugeri.it (G.B. Migliori), jaimuller@hotmail.com (J.B. Mullerpattan), dra_munoz@hotmail.com (M. Munoz-Torrico), drhamdanmh@gmail.com (H. Mustafa Hamdan), nmmagnolia@hotmail.com (M. Nieto Marcos), noorlizanoordin9@gmail.com (N.M. Noordin), djpalmero@intramed.net (D.J. Palmero), fabrizio.palmieri@inmi.it (F. Palmieri), christine_payen@stpierre-bru.be (M.-C. Payen), albertopiubello@yahoo.it (A. Piubello), pontals@yahoo.com (E. Pontali), agostinapontarelli@gmail.com (A. Pontarelli), saraiquirós@icloud.com (S. Quirós), adrianrendon@hotmail.com (A. Rendon), alena.skrahina@gmail.com (A. Skrahina), a_smite@inbox.lv (A. Šmite), solovic@hagy.sk (I. Solovic), gsotgiu@uniss.it (G. Sotgiu), bachirsoul@gmail.com (M.B. Souleymane), antonio.spanevello@icsmaugeri.it (A. Spanevello), maja_stosic@batut.org.rs (M. Stošić), mtadolini@hotmail.com (M. Tadolini), simon.tiberi@bartshealth.nhs.uk (S. Tiberi), zfu@hindujahospital.com (Z.F. Udwardia), vandenboom@who.int (M. van den Boom), marisavescovo@yahoo.com.ar (M. Vescovo), pietro.viggiani@asst-val.it (P. Viggiani), dina.visca@icsmaugeri.it (D. Visca), dmitry_zhurkin@yahoo.com (D. Zhurkin), zignolm@who.int (M. Zignol).

<https://doi.org/10.1016/j.ijid.2019.03.036>

1201-9712/© 2019 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

- ^a University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlands
- ^b University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases & Tuberculosis, Groningen, The Netherlands
- ^c Department of Phthisiology, Grodno State Medical University, GRCC “Phthisiology”, Grodno, Belarus
- ^d Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
- ^e Westmead Hospital, Sydney, Australia
- ^f Dept. Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands
- ^g Preventive Medicine Department, Ministry of Health and Prevention, Dubai, United Arab Emirates
- ^h Servicio de Neumología, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias CIBER-Enfermedades Respiratorias. Instituto de Salud Carlos III, Oviedo Spain
- ⁱ Moscow Research and Clinical Center for TB Control, Moscow Government's Health Department, Moscow, Russian Federation
- ^j Unidad de Enfermedades Infecciosas, Hospital General Universitario Reina Sofia, Murcia, Spain
- ^k Department of Pulmonary Diseases, Radboud Center of Infectious Diseases, Tuberculosis Center Dekkerswald Groesbeek, Radboud University Medical Center, Nijmegen, The Netherlands
- ^l Division of Infectious Diseases, Department of Medicine, Solna, Karolinska Institute, Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
- ^m Internal Medicine Department, Hospital General de Villalba, Collado Villalba, Spain
- ⁿ Zhejiang Integrated Traditional and Western Medicine Hospital, Hangzhou, China
- ^o Pneumology Department, Hospital General de Gran Canaria “Dr. Negrin”, Las Palmas de Gran Canaria, Spain
- ^p MDR-TB Unit, Tuberculosis Division, International Union against Tuberculosis and Lung Disease (The Union), Paris, France
- ^q Unidad de Neumología, Agencia Sanitaria Costa del Sol, Marbella, Spain
- ^r Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy
- ^s TB Reference Centre, Villa Marelli Institute/Niguarda Hospital, Milan, Italy
- ^t Public Health Consulting Group, Lugano, Switzerland
- ^u Reference Center Hélio Fraga, Fundação Oswaldo Cruz (Fiocruz)/Ministry of Health, Rio de Janeiro, Brazil
- ^v Clinic of Chest Diseases, Immunology and Allergology, Vilnius University Medical Faculty, Centre of Pulmonology and Allergology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
- ^w World Health Organization, Regional Office for Europe, Copenhagen, Denmark
- ^x National TB registry, Public Health Department, Ministry of Health; Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
- ^y Centro de Excelencia de TBMDR, Hospital Nacional Maria Auxiliadora, Lima, Peru
- ^z Victorian Tuberculosis Program, Melbourne Health; Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
- ^A National Reference Centre for MDR-TB, Hospital Centre Vila Nova de Gaia, Department of Pneumology; Public Health Science and Medical Education Department, Faculty of Medicine, University of Porto, Porto, Portugal
- ^B MDR-TB Department, Abu anga Teaching Hospital, Khartoum, Sudan
- ^C Department of Respiratory Medicine, P.D. Hinduja National Hospital and MRC, Mumbai, India
- ^D Pulmonology Division, Municipal Hospital F.J. Muñiz, Buenos Aires, Argentina
- ^E Tuberculosis Research Programme, SEPAR, Barcelona, Spain
- ^F Sociedad Colombiana de Neumología, Universidad Tecnológica de Pereira, Pereira, Colombia
- ^G National Institute of Respiratory and Environmental Diseases “Prof. Dr. Juan Max Boettner” Asunción, Paraguay
- ^H Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases ‘L. Spallanzani’, IRCCS, Rome, Italy
- ^I National Tuberculosis Programme, Skopje, Macedonia
- ^J National TB Surveillance Unit, Public Health Agency, Stockholm, Sweden
- ^K Northern State Medical University, Arkhangelsk, Russian Federation
- ^L MDR-TB department, Riga East University Hospital for TB and Lung Disease Centre, Riga, Latvia
- ^M Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
- ^N Universidad Autónoma de Baja California, Baja California, Mexico; Clínica de Tuberculosis del Hospital General de Tijuana, Tijuana, Baja California, Mexico
- ^O Departments of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China
- ^P S. Bortolo Hospital, Vicenza, Italy
- ^Q Department of Infectious Diseases, University National San Antonio Abad Cusco, Cusco, Peru
- ^R University Department of Infectious and Tropical Diseases, WHO Collaborating Centre for TB/HIV co-infection and for TB elimination, University of Brescia and Brescia Spedali Civili General Hospital, Brescia, Italy
- ^S Internal Medicine Department, Tuberculosis Hospital de Cantoblanco- Hospital La Paz, Madrid, Spain
- ^T Clínica de Tuberculosis, Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, Mexico
- ^U Hospital Doctor Moliner, Valencia, Spain
- ^V Disease Division, National Public Health Laboratory, Ministry of Health, Selangor, Malaysia
- ^W Division of Infectious Diseases, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium
- ^X Tuberculosis Division, International Union against Tuberculosis and Lung Disease (The Union), Paris, France
- ^Y Tuberculosis Division, Damien Foundation, Niamey, Niger
- ^Z Department of Infectious Diseases, Galliera Hospital, Genova, Italy
- ^{aA} Reference Centre for MDR and HIV-TB, Eugenio Morelli Hospital, Sondalo, Italy
- ^{aB} Pneumology Department, Tuberculosis Unit, Hospital de Cantoblanco- Hospital General Universitario La Paz, Madrid, Spain
- ^{aC} Centro de Investigación, Prevención y Tratamiento de Infecciones Respiratorias CIPTIR, University Hospital of Monterrey UANL (Universidad Autónoma de Nuevo Leon), Monterrey, Mexico
- ^{aD} Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus
- ^{aE} National Institute for TB, Lung Diseases and Thoracic Surgery, Vysne Hagy, Catholic University Ruzomberok, Slovakia
- ^{aF} Clinical Epidemiology and Medical Statistics Unit, Department of z, University of Sassari, Sassari, Italy
- ^{aG} Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy
- ^{aH} Department of Medicine and Surgery, Respiratory Diseases, University of Insubria, Varese, Italy
- ^{aI} TB Programme and Surveillance Unit, National Public Health Institute, Belgrade, Serbia
- ^{aJ} Unit of Infectious Diseases, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy
- ^{aK} Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom
- ^{aL} Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland

ARTICLE INFO

Article history:

Received 22 March 2019

Received in revised form 29 March 2019

Accepted 29 March 2019

Corresponding Editor: Eskild Petersen, Aarhus, Denmark

Keywords:

Tuberculosis

MDR-TB

Adverse events

Monitoring

Delamanid

Bedaquiline

ABSTRACT

The World Health Organization launched a global initiative, known as aDSM (active TB drug safety monitoring and management) to better describe the safety profile of new treatment regimens for drug-resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difficult to implement in several countries.

The aim of the aDSM project is to demonstrate the feasibility of implementing national aDSM registers and to describe the type and the frequency of adverse events (AEs) associated with exposure to the new anti-TB drugs.

Following a pilot study carried out in 2016, official involvement of TB reference centres/countries into the project was sought and cases treated with bedaquiline- and/or delamanid-containing regimens were consecutively recruited. AEs were prospectively collected ensuring potential attribution of the AE to a specific drug based on its known safety profile.

A total of 309 cases were fully reported from 41 centres in 27 countries (65% males; 268 treated with bedaquiline, 20 with delamanid, and 21 with both drugs) out of an estimated 781 cases the participating countries had committed to report by the first quarter of 2019.

© 2019 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

The World Health Organization (WHO) seeks global evidence on the safety and tolerability of new treatment regimens for drug-resistant tuberculosis, including multidrug-resistant tuberculosis (MDR-TB) (Halleux et al., 2018).

The WHO launched a comprehensive approach, known as aDSM (active TB drug safety monitoring and management) (World Health Organization, 2015), proposing that national programmes implement ‘active and systematic clinical and laboratory assessment of patients on treatment with new TB medicines, or novel MDR-TB or XDR (extensively drug-resistant)-TB regimens to detect, manage and report suspected or confirmed drug toxicities’ (Halleux et al., 2018). This initiative is really important as, after more than 40 years without any new drug specifically licensed to manage TB, we finally have bedaquiline and delamanid (Borisov et al., 2017; Kim et al., 2018; Kuksa et al., 2017; Mohr et al. 2018; Pontali et al., 2017; Pontali et al., 2018; Pym et al., 2016).

Although some information on safety of the new drugs has been made available, more clinical details (to obtain through extensive surveillance of adverse events (AEs)) are required. This is particularly relevant in view of the potential bedaquiline, delamanid, clofazimine, and quinolones have to increase the QT interval (Pontali et al., 2017) and generate an arrhythmic event. Therefore, the real-time monitoring of anti-TB regimens is fully justified (Halleux et al., 2018; World Health Organization, 2015). Of course, although any kind of AE requires prompt clinical action, special attention is necessary on serious AEs, as they are potentially life-threatening. In particular, according to the WHO aDSM project serious AEs include death or a life-threatening experience, hospitalization or prolongation of hospitalization, persistent or significant disability, or congenital anomaly (Halleux et al., 2018; World Health Organization, 2015).

The WHO proposal to national programmes was to initiate regular monitoring of AEs, as well as collect and report information




Figure 1. Map of the participating countries.

Red: Countries which regularly reported; Green: Countries in the process of reporting; Blue: Countries which activated active monitoring of adverse events with no cases yet treated with new drugs.

on bacteriological status at diagnosis (sputum smear, culture, drug resistance profile), bacteriological conversion/reversion (sputum smear and culture conversion rates) and treatment outcomes (Halleux et al., 2018). The surveillance methodology has been left to countries which were supposed to use electronic registers or existing electronic medical record systems (Halleux et al., 2018), complementing, rather than duplicating, national pharmacovigilance initiatives.

WHO also launched a global aDSM database to collect a standard set of variables including anonymised individual-level patient data on serious AEs (Halleux et al., 2018), and provided clear guidance on how to implement aDSM at a national level (World Health Organization, 2015).

National TB Programmes faced difficulties in implementing aDSM and contributing to the global database. Taking advantage of a newly implemented global network (Global Tuberculosis Network-GTN) (Borisov et al., 2017; Rossato Silva et al., 2018) a large aDSM project was launched to demonstrate the feasibility of implementing national aDSM registers. The GTN research addressed clinical centres with the goal of assessing the safety and tolerability profile, as well as the effectiveness of anti-TB drugs

and regimens in MDR-TB patients treated with new drugs (bedaquiline, delamanid) worldwide. The WHO initiative is focused on National Tuberculosis Programmes in order to evaluate the safety of anti-TB regimens. The two initiatives are co-ordinated.

After a pilot study was implemented in 2016 in a few centres to assess the suitability of the project and its potential implementation, and following the approval of the coordinating centre's Ethics Committee (July 11th, 2017), the project was proposed to the clinical centres or national programmes participating in the network. Each centre or country signed a confidentiality and data-sharing agreement with the coordinating centre and obtained local Ethics Committee clearance as per legislation in force.

All consecutive cases for which bedaquiline and/or delamanid were prescribed since the moment the centre or country adhered to the project were enrolled. The AEs of any drug involved in the treatment regimen were prospectively collected, ensuring a probabilistic mechanism of causality assignment (e.g. attribution of the AE to a specific drug based on its evidence-based profile). The data collection form in an electronic format was based on the WHO-recommended template, although more clinical details were requested (World Health Organization, 2015).

Table 1
Participating countries and details on the cases reported.

Countries	Estimated cases ^a N	Estimated coverage ^b %	Cases enrolled N	Male N (%)	Cases treated with Bdq N (%)	Cases treated with Dlm N (%)	Cases treated with Bdq-Dlm or Dlm-Bdq consecutively N (%)	Cases treated with Bdq-Dlm in combination N (%)
EUROPE								
Belgium	3	60	3	2 (67)	3 (100)	0 (0)	0 (0)	0 (0)
Belarus ^f	113	80	27	17 (63)	20 (74)	7 (26)	0 (0)	0 (0)
Italy ^g	29	80	27	17 (63)	20 (74)	6 (25)	0 (0)	1 (4)
Latvia	30	100	30	18 (60)	20 (40)	3 (10)	1 (3)	6 (20)
Lithuania	170	100	Data uploading	–	–	–	–	–
Macedonia	No cases	100	–	–	–	–	–	–
Netherlands ^f	6	100	6	5 (83)	3 (50)	0 (0)	1 (17)	2 (33)
Portugal	1	100	1	1 (100)	0 (0)	1 (100)	0 (0)	0 (0)
Russian Federation ^f	257	100 ^c	140	87 (62)	135 (96)	2 (1)	1 (0.7)	2 (1)
Serbia	No cases	100	–	–	–	–	–	–
Slovakia	1	100	1	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)
Spain ^g	9	100	1	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)
Sweden	16	100	5	2 (40)	4 (80)	0 (0)	1 (20) ⁱ	0 (0)
United Kingdom	4	20	4	2 (50)	4 (100)	0 (0)	0 (0)	0 (0)
AFRICA								
Niger	21	100	13	13 (100)	10 (77)	0 (0)	0 (0)	3 (23)
Sudan	5	100	2	2 (100)	2 (100)	0 (0)	0 (0)	0 (0)
LATIN AMERICA								
Argentina	11	100	3	0 (0)	3 (100)	0 (0)	0 (0)	0 (0)
Brazil	33	100	26	22 (85)	26 (100)	0 (0)	0 (0)	0 (0)
Colombia	No cases	100	–	–	–	–	–	–
Mexico ^f	8	100	4	3 (75)	1 (25)	1 (25)	0 (0)	2 (50)
Paraguay	No cases	100	–	–	–	–	–	–
Peru	30	80	Data uploading	–	–	–	–	–
ASIA								
China ^h	5	100 ^d	Data uploading	–	–	–	–	–
India	15	100 ^e	10	5 (50)	9 (90)	0 (0)	1 (10)	0 (0)
Malaysia ^h	8	100	Data uploading	–	–	–	–	–
United Arab Emirates	No cases	–	–	–	–	–	–	–
OCEANIA								
Australia	6	100 ^e	6	4 (67)	6 (100)	0 (0)	0 (0)	0 (0)
TOTAL 27	781	Range 20%–100%	309	200 (65)	268 (87)	20 (7)	5 (2)	16 (5)

^a Cases estimated by countries to be fully reported by 1st quarter 2019.

^b Countries' estimate of the national coverage of the aDSM project on new drugs.

^c In the 2 Oblasts reporting.

^d In the Province reporting.

^e In the State reporting.

^f 2 centres.

^g 6 centres.

^h 1 centre.

ⁱ Case with Dlm for 4 days only, not concomitant with Bdq.

This article reports on the initial results of the aDSM project.

As of January 31st 2019 (interim analysis), 41 centres in 27 countries (Figure 1, Table 1) provided aDSM information on new anti-TB drugs: 14 in Europe, 6 in Latin America, 4 in Asia, 2 in Africa, and 1 in Oceania. 5 countries participated in the aDSM project although no case has yet been treated with bedaquiline and/or delamanid.

This resulted in 100% coverage for the majority of the countries, while in some of them the actual coverage was lower. In the Russian Federation 2 Regions (Moscow and Arkhangelsk Oblasts) are represented with 100% coverage, as well as the Victoria State in Australia and the Zhejiang Province in China.

A total of 309 cases were fully reported from January 2016 to January 2019 (65% males; 268 treated with bedaquiline, 20 with delamanid and 21 with the two drugs prescribed in combination or consecutively) out of the estimated 781 cases the participating countries committed to report in the first quarter 2019.

The recruitment process in all continents was long and time-consuming, although the support and enthusiasm of the participating colleagues allowed for resolution of any existing problems. Several countries (including Sub-Saharan Africa) were asked to participate, but some centres decided to decline as the project is on a voluntary basis and the activity is perceived as 'difficult' 'or time-consuming' without provision for additional resources.

During the 'interim analysis', planned in the second quarter 2019, AEs will be analysed separately both per drug (bedaquiline, delamanid, linezolid, fluoroquinolones, clofazimine, etc.) and per 'severity' status.

To our knowledge, this is the first published evidence of a global aDSM project in the literature.

Conflict of interest statement

No competing interest declared.

Funding sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethical approval

Approval was not required.

Acknowledgements

The project is supported by the Global Tuberculosis Network (GTN; Committees on TB Treatment, Clinical trials and Global TB Consilium) and was part of the European Respiratory Society Latin American project in collaboration with ALAT (Asociación Latino Americana de Torax - Latino American Thoracic Association) and SBPT (Brazilian Society of Pulmonology and Tuberculosis).

This article belongs to the scientific activities of the WHO Collaborating Centre for Tuberculosis and Lung Diseases, Tradate, ITA-80, 2017-2020- GBM/RC/LDA.

References

- Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis: a multicentre study. *Eur Respir J* 2017;49(5) pii: 1700387.
- Halleux CM, Falzon D, Merle C, Jaramillo E, Mirzayev F, Olliaro P, et al. The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis. *Eur Respir J* 2018;51:1701643. doi:http://dx.doi.org/10.1183/13993003.01643-2017.
- Kim CT, Kim TO, Shin HJ, Ko YC, Hun Choe Y, Kim HR, et al. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multi-center cohort study in Korea. *Eur Respir J* 2018;51:1702467.
- Kuksa L, Barkane L, Hittel N, Gupta R. Final treatment outcomes of multidrug and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens. *Eur Respir J* 2017;50(5) pii: 1701105.
- Mohr E, Hughes J, Reuter A, Trivino Duran L, Ferlazzo G, Daniels J, et al. Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa. *Eur Respir J* 2018;51(6) pii:1800017.
- Pontali E, Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Migliori GB. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. *Eur Respir J* 2017;50(5) pii: 1701462.
- Pontali E, Sotgiu G, Tiberi S, Tadolini M, Visca D, D'Ambrosio L, et al. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. *Eur Respir J* 2018;52(1) pii: 1800934.
- Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. *Eur Respir J* 2016;47(2):564–74.
- Silva DR, Rendon A, Alffenaar JW, Chakaya JM, Sotgiu G, Esposito S, et al. Global TB Network: working together to eliminate tuberculosis. *J Bras Pneumol* 2018;44(5):347–9.
- World Health Organization. Active TB drug-safety monitoring and management (aDSM). WHO/HTM/TB/2015.28. Geneva: World Health Organization; 2015 Available at: https://apps.who.int/iris/bitstream/handle/10665/204465/WHO_HTM_TB_2015.28_eng.pdf?jsessionid=5C686C3810B82414B13C6FD189EAB254?sequence=1. [Last accessed 6 February 2019].